ACLARION, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
ACLARION, INC. (ACON) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $226.92 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2024-03-28
- ACLARION, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $226.92K, a 320.90% increase from fiscal 2022.
- ACLARION, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $53.91K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|
| 2023-12-31 | $226.92K 10-K · filed 2024-03-28 |
| 2022-12-31 | $53.91K 10-K/A · filed 2023-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |